Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

Fig. 5

Right ventricular dimensions and function. a Representative cardiac MRI images of the right ventricle (RV) at baseline (V0) and at Day 180 (V11) in the placebo and UC-MSC groups. Changes (Δ) in RV end-systolic volume (RVESV) and RV end-diastolic volume (RVEDV) from baseline (V0) to (b) Day 180 (V11) (n = 12 in placebo group, n = 14 in UC-MSCs group) and (c) Day 360 (V12) (n = 11 in placebo group, n = 14 in UC-MSCs group), measured by cardiac MRI. d Changes (Δ) in tricuspid annular plane systolic excursion (TAPSE) from baseline (V0) to Day 180 (V11) (n = 18 in placebo group, n = 19 in UC-MSCs group) and Day 360 (V12) (n = 19 in placebo group, n = 18 in UC-MSCs group), measured by echocardiography. P values were calculated using independent t-tests. Data are presented as mean ± SEM. Red P values indicate P < α (0.05)

Back to article page